---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-018277"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:03:42.354517+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Belapectin shows 49.3% reduction in new varices in MASH cirrhosis patients at EASL 2025

## Summary
- Belapectin 2 mg/kg reduced new varices by 49.3% vs placebo (p=0.04) in per-protocol population (n=287).
- Only 4.3% of 2 mg/kg group had >10 kPa liver stiffness increase vs 12.5% placebo (p=0.02).
- Safety profile comparable to placebo; no drug-related serious adverse events reported.
- NAVIGATE trial: 355 patients randomized 1:1:1 to belapectin 2/4 mg/kg or placebo every other week for 18 months.
- Data presented as late-breaking oral at EASL 2025 Congress on May 10, 2025 in Amsterdam.

## SEC filing metadata
- accession: 0001140361-25-018277
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036125018277/0001140361-25-018277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036125018277/ef20048562_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-018277
- JSON: https://secwatch.observer/filing/0001140361-25-018277.json
- Plain text: https://secwatch.observer/filing/0001140361-25-018277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.